{"id":50374,"date":"2022-11-02T13:02:20","date_gmt":"2022-11-02T12:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/"},"modified":"2022-11-02T13:02:20","modified_gmt":"2022-11-02T12:02:20","slug":"lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/","title":{"rendered":"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022"},"content":{"rendered":"
\n

ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (\u201cLENSAR\u201d or \u201cthe Company\u201d), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company\u2019s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022. LENSAR\u2019s management will host a conference call and webcast at 8:30 am ET on Wednesday, November 9, 2022 to discuss the financial results and recent corporate highlights.\n<\/p>\n

<\/a><\/p>\n

\nTo participate by telephone, please dial (888) 396 8049 (Domestic) or 416 764 8646 (International). The conference ID number is 51285282. To access the live webcast, please go to the Investors section of LENSAR\u2019s website at www.lensar.com<\/a>. Following the live webcast, an archived version of the call will be available on the website.\n<\/p>\n

\nAbout LENSAR<\/b>\n<\/p>\n

\nLENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of visually significant astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY\u2122 Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform cataract surgery by utilizing LENSAR\u2019s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR\u2019s proprietary Streamline\u00ae software technology, designed to guide surgeons to achieve better outcomes.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nThomas R. Staab, II, CFO
\n
ir.contact@lensar.com<\/a>\n<\/p>\n

\nLee Roth \/ Cameron Radinovic
\n
Burns McClellan for LENSAR
\n
lroth@burnsmc.com<\/a> \/ cradinovic@burnsmc.com<\/a>\n<\/p>\n

\n\u00a0\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (\u201cLENSAR\u201d or \u201cthe Company\u201d), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company\u2019s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022. LENSAR\u2019s management will host a conference call … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50374","6":"format-standard","7":"category-industry"},"yoast_head":"\nLENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (\u201cLENSAR\u201d or \u201cthe Company\u201d), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company\u2019s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022. LENSAR\u2019s management will host a conference call ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-02T12:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221101006280\/en\/1621603\/21\/LNSR_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022\",\"datePublished\":\"2022-11-02T12:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/\"},\"wordCount\":277,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101006280\\\/en\\\/1621603\\\/21\\\/LNSR_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/\",\"name\":\"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101006280\\\/en\\\/1621603\\\/21\\\/LNSR_Logo.jpg\",\"datePublished\":\"2022-11-02T12:02:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101006280\\\/en\\\/1621603\\\/21\\\/LNSR_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101006280\\\/en\\\/1621603\\\/21\\\/LNSR_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/","og_locale":"en_US","og_type":"article","og_title":"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022 - Pharma Trend","og_description":"ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (\u201cLENSAR\u201d or \u201cthe Company\u201d), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company\u2019s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022. LENSAR\u2019s management will host a conference call ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-02T12:02:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221101006280\/en\/1621603\/21\/LNSR_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022","datePublished":"2022-11-02T12:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/"},"wordCount":277,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221101006280\/en\/1621603\/21\/LNSR_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/","url":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/","name":"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221101006280\/en\/1621603\/21\/LNSR_Logo.jpg","datePublished":"2022-11-02T12:02:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221101006280\/en\/1621603\/21\/LNSR_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221101006280\/en\/1621603\/21\/LNSR_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lensar-to-report-third-quarter-2022-financial-results-on-wednesday-november-9-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50374"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50374\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}